[{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Public Offering","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Jefferies","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Jefferies"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Series B Financing","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Jazz Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Licensing Agreement","leadProduct":"WTX-613","moa":"INF-alpha receptor","graph1":"Oncology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Jazz Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf Therapeutics \/ Jazz Pharmaceuticals"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"WTX-124","moa":"IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Pembrolizumab","moa":"||IL-2","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"WTX-330","moa":"IL-12 receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Werewolf Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"WTX-921","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"Werewolf Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Werewolf Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Werewolf Therapeutics \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals by Werewolf Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-921 is a novel IL-10 indukine development candidate for Inflammatory Bowel Disease (IBD) and potentially other inflammatory diseases.

                          Product Name : WTX-921

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          October 31, 2024

                          Lead Product(s) : WTX-921

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-330 is designed to be a systemically dosed prodrug with the ability to deliver fully active IL-12 selectively. Currently, it is being evaluated for the treatment of neoplams.

                          Product Name : WTX-330

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          June 25, 2024

                          Lead Product(s) : WTX-330

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-330 has the potential to be the only systemic, conditionally active IL-12 therapy with normal tissue IL-12R receptor blockade to deliver the full potency of IL-12 directly to the tumor microenvironment.

                          Product Name : WTX-330

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          February 24, 2023

                          Lead Product(s) : WTX-330

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Study data demonstrate that systemic administration of WTX-330, a mouse surrogate INDUKINE molecule, generates potent anti-tumor activity in a cleavage-dependent manner and protective memory against re-challenge in multiple murine syngeneic tumor models.

                          Product Name : WTX-330

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 11, 2022

                          Lead Product(s) : WTX-330

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-124 and WTX-330 INDUKINE molecules consist of wild-type IL-2 and IL-12 cytokines, tethered to an inactivation domain to prevent activation in peripheral tissue, to allow for activation in tumor microenvironment, and a half-life extension to improve t...

                          Product Name : WTX-124

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          August 04, 2022

                          Lead Product(s) : WTX-124,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Merck & Co

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Under the agreement, Jazz has acquired exclusive global development and commercialization rights to Werewolf's investigational WTX-613, a differentiated, conditionally-activated interferon alpha (IFNα) INDUKINE™ molecule in tumors.

                          Product Name : WTX-613

                          Product Type : Protein

                          Upfront Cash : $15.0 million

                          July 04, 2022

                          Lead Product(s) : WTX-613

                          Therapeutic Area : Oncology

                          Highest Development Status : Preclinical

                          Sponsor : Jazz Pharmaceuticals

                          Deal Size : $1,275.0 million

                          Deal Type : Licensing Agreement

                          blank

                          07

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Preclinical data show that WTX-124 has an improved therapeutic window compared to recombinant human IL-2 in mouse models and the potential to minimize the toxicity associated with systemic IL-2 administration.

                          Product Name : WTX-124

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          March 16, 2022

                          Lead Product(s) : WTX-124

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-124 design consists of wild-type IL-2 cytokine tethered to an inactivation domain to prevent activation in off-target tissue, tumor protease-sensitive linker to allow for activation in tumor micro-environment and half-life extension domain to improve...

                          Product Name : WTX-124

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          January 09, 2022

                          Lead Product(s) : WTX-124,Pembrolizumab

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : Company's most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE™ molecules, respectively, for the treatment of solid tumors.

                          Product Name : WTX-124

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          October 27, 2021

                          Lead Product(s) : WTX-124

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          10

                          Interphex
                          Not Confirmed
                          Interphex
                          Not Confirmed

                          Details : WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINE molecules, respectively, for the treatment of solid tumors.

                          Product Name : WTX-124

                          Product Type : Protein

                          Upfront Cash : Inapplicable

                          September 14, 2021

                          Lead Product(s) : WTX-124

                          Therapeutic Area : Oncology

                          Highest Development Status : IND Enabling

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank